Colfax CORP: insider trades · United States · SEC (Form 4)

About Colfax CORP

Colfax CORP (ticker: CFX) is historically a U.S.-listed industrial group, quoted on the NYSE/NASDAQ universe, with a long operating history in industrial technology. For French-speaking investors, one critical nuance matters: the legal entity tied to ticker CFX underwent major corporate restructuring. SEC filings show that after the business separation, the company changed its name to Enovis Corporation and its stock began trading under the new ticker ENOV in April 2022. As a result, the most detailed operational disclosures available in recent filings relate mainly to the former Colfax structure that became Enovis, while CFX is best understood as the historical ticker and market documentation of that legacy configuration. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1420800/000142080023000023/cfx-20230630.htm?utm_source=openai)) Originally, Colfax built its profile as a diversified industrial company spanning fabrication technology and medical technology. Recent SEC annual reports describe a portfolio focused on industrial manufacturing and healthcare end markets, with well-known brands and business lines such as ESAB and DJO, and later segment structures such as Prevention & Recovery and Reconstructive. In medical technology, the company offered rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, compression systems, and rehabilitation products. On the fabrication side, it was exposed to welding, fabrication consumables, equipment, and related industrial solutions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1420800/000142080021000009/cfx-20201231.htm?utm_source=openai)) From a corporate history standpoint, Colfax was notable for an active portfolio strategy, using divestitures and separations to streamline the business around higher-growth, higher-margin end markets. A 2021 SEC filing confirms the plan to split the fabrication and medical technology businesses into two independent public companies, a process that ultimately led to the name change and spin-off completion in 2022. The company’s headquarters were listed as Annapolis Junction, Maryland in earlier filings, while more recent reports cite Wilmington, Delaware. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1420800/000119312521068378/d146076dex991.htm?utm_source=openai)) In competitive terms, Colfax operated in specialized industrial niches where product innovation, global distribution, and after-sales service matter significantly. Its international footprint, as disclosed in SEC filings, gave it access to industrial and healthcare customers across multiple geographies. The key recent developments investors should track are the business separation, the rebranding to Enovis, and the continued appearance of CFX-related market documentation and insider transaction filings (Form 4). For market monitoring, it is important to verify in real time whether CFX still maps to a tradable legacy vehicle or to a residual corporate structure, because the restructuring materially changed the economic interpretation of the name. ([ir.colfaxcorp.com](https://ir.colfaxcorp.com/static-files/39377599-00a9-4a40-811b-5612653b14cc?utm_source=openai))